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ABSTRACT 
BACKGROUND / OBJECTIVES: 
Stroke has many well established risk factors like diabetes mellitus, systemic 
hypertension, dyslipidemia, atrial fibrillation and smoking. Vitamin D is being 
looked upon as one of the latest risk factors. Our aim was to find out the 
association between Vitamin D and acute ischaemic stroke, and the effect of 
parameters like age, gender, obesity and dyslipidemia on Vitamin D levels. 
MATERIALS AND METHODOLOGY: 
Cross sectional study of 100 subjects – 50 patients with acute ischaemic stroke and 
50 age and sex matches controls without stroke, studied consecutively at Kilpauk 
Medical College Hospital, Chennai. Serum 25 Hydroxy Vitamin D levels were 
measured along with Body Mass Index, LDL cholestrol, HDL cholestrol, 
Triglycerides and Total Cholestrol. 
RESULTS: 
Stroke patients had significant Vitamin D deficiency (mean-13.48ng/ml, p 
value<0.01) when compared to controls (mean 23.03ng/ml). Gender variation and 
smoking did not affect the Vitamin D levels. Vitamin D was found to be 
significantly lower in cases with age less than 40yrs (p-0.046). Vitamin D levels 
were not affected Body Mass Index or lipid levels. 
CONCLUSION: 
Acute ischaemic stroke patients have significant Vitamin D deficiency. Vitamin D 
deficiency could be the causative factor for stroke in these patients. Correction of 
Vitamin D status can prevent stroke in Vitamin D deficient individuals. 
 
KEYWORDS 
25 hydroxy Vitamin D, Gender, Age, Body Mass Index, Dyslipidemia, Stroke 
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INTRODUCTION 
    One of the commonest causes of morbidity and mortality worldwide is 
cerebrovascular accident, commonly referred to as stroke. Stroke accounts for 
1% of mortality among hospital deaths in India, with an incidence of 4% of 
admissions in Medical wards and overall incidence of 20% of all patients 
admitted with neurologic disorder1. The term ‘stroke’ is applied to a sudden 
focal neurologic syndrome, mainly the type caused by cerebrovascular disease.     
    This term cerebrovascular disease points towards any abnormality of 
the brain resulting from a pathologic process of the blood vessels, occlusion of 
the lumen by embolus or thrombus, vessel rupture, altered permeability of the 
vessel wall, or hyperviscosity or other change in the quality of the blood 
flowing through the cerebral vessels. The prevalence of stroke has rapidly 
increased in the past few years.  
     Stroke has many well established risk factors like diabetes mellitus, 
systemic hypertension, dyslipidemia, atrial fibrillation and smoking. Yet, there 
are a lot of cases where the risk factors are not identified. Hence, a lot of 
epidemiological studies are being carried out to identify emerging novel risk 
factors and they continue to be an aspect of debate regarding their role in 
reducing incidence of stroke and their exact nature of association with stroke. 
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   Over the recent years, one such risk factor i.e. Vitamin D Deficiency 
has been given much emphasis. Vitamin D is a steroid molecule and one of the 
lipid soluble vitamins. It is mainly produced by the skin from cholestrol and 
also absorbed from the gut. As knowledge emerges of its biological functions, it 
is attracting importance from many nutritional and medical communities. In the 
last few years, its association with decreased risk of many chronic diseases as 
been the talk of the town. 
    Vitamin D deficiency is a worldwide health problem. In addition to its 
well accepted role as a major regulator of calcium and bone metabolism, many 
studies have shown strong association of hypovitaminosis D with systemic 
hypertension, coronary artery disease, diabetes mellitus, heart failure, metabolic 
syndrome, cancer, peipheral artery disease and many autoimmune disorders. 
      Few worldwide studies have shown association between Vitamin D 
deficiency and an increased incidence of Cerebrovascular Accident ( Stroke). 
Vitamin D deficiency is postulated to cause endothelial dysfunction.This plays a 
vital role in the pathogenesis of stroke. Following the discovery of the 
expression of Vitamin D receptors and 1α hydroxylase in the endothelium of 
blood vessels, several biological mechanisms that link Vitamin D with stroke 
and its risk factors have been identified. Vitamin D acts mainly through its role 
in maintaining gene transcription to prevent cerebrovascular disease and its risk 
factors. 
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     In spite of the rising proportion of stroke in Asians, only limited data 
is available on the relationship between Vitamin D and stroke. Since Vitamin D 
levels are directly measurable and its deficiency can be treated, many trials are 
being done to assess its association with stroke and to prevent stroke if possible.  
     A practical time to check 25-hydroxy vitamin D levels would be at the 
time of an acute ischaemic stroke. Hence this study was designed to assess the 
vitamin D levels in acute ischaemic stroke and to find out any significant 
correlation. 
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AIMS AND OBJECTIVES 
  
5 
 
 
AIMS AND OBJECTIVES 
 
1. The primary aim of the study was to measure the serum 25hydroxy-
Vitamin D levels in patients with acute ischaemic stroke and to compare 
their levels with age and sex matched controls. 
2. The secondary objectives were to assess the effect of age, sex, obesity, 
smoking and dyslipidemia on Vitamin D levels. 
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REVIEW OF LITERATURE 
STROKE 
DEFINITION: 
 A stroke or cerebrovascular accident is defined as neurological deficit 
that is abrupt in onset, attributable to a focal neurological cause, lasting more 
than 24hours.2 The term ‘cerebrovascular disease’ indicates any abnormality of 
the brain resulting from a pathologic process of the blood vessels, including 
rupture of a vessel, occlusion of the lumen by embolus or thrombus, increased 
viscosity or an altered permeability of the vessel wall, or any other change in 
the quality of the blood flowing through the cerebral vessels. 
STROKE STATISTICS – GLOBAL SCENARIO 
 In the recent years, due to the increase in the development of economy 
and demography, there is a shift towards lifestyle-related chronic non-
communicable diseases in the developing and developed countries. In the 
developing as well as developed countries, one of the causes of serious long 
term neurological disability is stroke. It also makes an important contribution to 
morbidity and mortality.  
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Worldwide, stroke  is the third most common cause of death following 
coronary artery disease and cancer.3 It is the fourth leading cause of disease 
burden3. More than the sixth decade, the prevalence of stroke is nearly three-
fourths more. There is no age limit for stroke to occur. One-fourths of the 
overall incidence of stroke occurs in people less than 65yrs of age.4 The stroke 
risk is doubled for each decade, after the age of 55yrs.5 
 The incidence of stroke in entire world population is 0.22 per 1000 
people. According to World Health Organisation (WHO) report, approximately 
around 15million people are struck by stroke every year. Out of these strokes, 
higher systemic hypertension contributes to 12.7 million. Out of the 15million 
people affected by stroke every year,around one third die and another one third 
have permanent disability.6 The number of people suffering from stroke in 
increasing in developing countries, largely due to the fact that systemic 
hypertension is not being controlled adequately. Smoking and ageing of the 
population as a whole also contributes significantly. 
STROKE – INDIAN SCENARIO: 
 When compared to few developed countries, where the incidence of 
stroke as reached a plateau or has even decreased, stroke burden as been 
increasing in India. In India, ischaemic stroke contributes to around 80% of all 
strokes.7 It is estimated that, by 2015, around 1.6 million cases of stroke will be 
reported annually. One third of these will have permanent disability. WHO has 
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estimated that by 2050, 80% of all strokes in the world will occur in India and 
China.7 Indian studies show that about  10-15% of all strokes occur in people of 
less than 40yrs of age. 
RISK FACTORS FOR STROKE 
Non- Modifiable risk factors2 
• Old age 
• Male sex 
• Post menopausal women 
• Type A personality 
• Family history 
• Genetic factors 
Modifiable risk factors 
• Diabetes mellitus 
• Systemic hypertension 
• Dyslipidemia 
• Smoking 
• Obesity 
• Stress 
• Sedentary habits 
10 
 
PATHOGENESIS OF STROKE 
 
 Considerable progressive development in the understanding of the 
physiology and pathogenesis of acute ischaemic stroke has taken place in the 
last two decades. Ischaemic cascade is the series of time dependent 
neurochemical events that take place after occlusion of the intracranial cerebral 
vessels. The flow disturbance causes rapid, secondary and delayed effects. 
Rapid effects – oxygen depletion, energy failure, terminal depolarization and 
ion homeostasis failure. It occurs within minutes. 
Secondary effects – excitotoxicity, SD-like depolarizations and disturbance of 
ion homeostasis. It occurs within hours. 
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Delayed effects – inflammation and apoptosis. It occurs in few days to few 
weeks of onset of flow disturbance. 
The neuropathogenic processes involved in the ischaemic insult are- 
• An excitatory aminoacid, glutamate, is the most excessive excitatory 
neurotransmitter in the brain. It is stored in the presynaptic vesicles. Upon 
release, it binds to the post synaptic NMDA ( N-methyl D-aspartate) 
receptor.8 
• Once the reduction of cerebral blood flow commences, abundant release 
of excitatory neurotransmitters occurs, mainly glutamate, causing 
excessive activation of the NMDA receptor. 
• Once these receptors get activated, there is excessive influx of sodium 
and calcium ions through the voltage and ligand gated channels. 
• The intracellular enzyme systems lead to the induction of- 
i. Free radical production9 
ii. Initiation of an inflammatory response which stimulates apoptosis 
iii. Membrane lipid breakdown proteolysis 
• Compromise of metabolic functions occurs with expansion of the infarct 
volume and neurotoxicity over days to weeks. 
• Direct microvascular damage and worsening ischaemia occurs as a result 
of leucocyte and platelet activation.10 
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MANAGEMENT OF STROKE 
  
RECENT TRENDS IN THE MANAGEMENT OF STROKE 
 Dramatic improvement in the management of ischaemic stroke has been 
seen in recent times. Therapeutic strategies have been divided into those 
targeting the nervous system and those targeting the vasculature. Current 
vascular strategies include recanalisation by clot removal ( thrombolysis, 
intraarterial fibrinolysis, mechanical removal) and prevention of propagation of 
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clot with aspirin and atorvastatin. Protection to the brain is given by these 
agents mainly through the hemodynamics rather than the metabolic 
mechanisms.11 
INTRAVENOUS THROMBOLYSIS 
 The use of intravenous thrombolytic therapy in acute ischaemic stroke is 
strongly time dependent.In the first few minutes of symptom onset, therapeutic 
yield is maximum. It declines steadily during the first three hours. The ‘golden 
hour’ for therapy is the first 60minutes of onset of symptoms. Recanalisation 
therapy has maximum benefit in this golden hour. Target door to needle time is 
<60mins. This is achieved in less than one fifth of golden hour-arriving patients. 
In a typical acute ishaemic stroke, every minute the brain loses 14 billion 
synapses, 7.5miles myelinated fibres and 1.9million neurons.12 1 fewer patient 
has improved for every 10minute delay in delivery of recombinant tissue 
plasminogen activator. 
 The window period for intravenous thrombolysis is 4.5 hours, that is, 4.5 
hours from the time of onset of stroke symptoms. Therapeutic window is the 
time until the area becomes irreversibly damaged.13 The window period for 
intravenous thrombolysis has been recently increased from 3 hours to 4.5 
hours.14 However, only a small proportion of patients reach the medical setups 
within this time frame. So, the majot target for management of stroke is in 
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protecting the brain from ischaemic damage and preventing the occurence of 
stroke. 
 Current neural strategies for treating acute ischaemic stroke include acute 
neuroprotection and promotion of brain plasticity. Various neuroprotective 
agents like calcium antagonists, free radical scavengers, glycine antagonists, 
etc, which intervene in one of the steps of ischaemic cell injury have been used 
in the past for treating ischaemic stroke.15 But they were either too toxic to 
humans or ineffective. 
THE NEED FOR NEUROPROTECTION: 
  Once ischaemic damage occurs, the neurological insult spreads from the 
core of the infarct. The maximal size of the infarct is produced by the 
excitotoxic injury which continues beyond 48 hours. For the next 72 hours, the 
local cerebral perfusion and autoregulation are disturbed.16 In most cases, within 
72-96 hours, collateral vessels develop and the damaged areas get reperfused. 
To some extent, the regional blood flow abnormalities also tend to resolve.17     
 The areas of ischaemia which will transform into an infarct cannot be 
identified even by Positron Emission Tomography (PET) imaging, which can 
usually distinguish ischaemia from infarct. It was found that within 9 hours of 
the insult, blood flow was reduced locally in 100% of patients and within 4 
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days, it was reduced to 30%. Even upto 48 hours after stroke, this ischaemic but 
viable tissue can be found.    
The time window for thrombolysis is relatively short because of the high 
hemorrhagic complications when reperfusion therapy is done at later stages. So 
there is a rationale for initiating neuroprotective measures in order to prevent 
the ongoing cerebral ischaemia. This also salvages the viable ischaemic tissue at 
a time when cerebral autoregulation is deranged.18  
CLASSIFICATION OF NEUROPROTECTIVE AGENTS8 
1. Modulators of Calcium Influx 
2. Modulators of Excitatory Amino Acids 
3. Metabolic Activators 
4. Inhibitors of  Leukocyte Adhesion 
5. Anti edema agents 
6. Promotors of Membrane Repair 
7. Free Radical Scavengers and Anti-Oxidants 
The most promising neuroprotective agents are the therapeutic  
hypothermia, hyperacute magnesium therapy, high dose human albumin, 
GABA agonists, calcium channel blockers, glutamate antagonists, down-
regulators of the nitric oxide signal transduction, free radical scavengers and 
antioxidants. These are the ones that have been most extensively studied.19 
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In recent times, many clinical trials conducted have proved the  
neuroprotection offered by Vitamin D and its role in preventing ischaemic 
stroke. 
PROGNOSIS: 
 The most common cause of neurological disability in the world is stroke. 
Patients with stroke have a worse morbidity than any type of cancer. 
Approximately, 75% of the patients affected with stroke become functionally 
dependent.20 The Indian Council of Medical Research (ICMR) estimated that 
stroke contributes for 72 % of Disability Adjusted Life Years (DALYS) and 
41% of deaths among the non-communicable diseases (NCDs).20 Many 
problems like seizures, fractures, falls, dementia and depression occur 
secondary to stroke. So, stroke patients have residual disabilities which make 
them physically dependent, causing enormous socio-economic impact on health 
care institutions, individuals and families. 
ISCHAEMIC PENUMBRA 
 It is defined as that region of the ischaemic zone that is potentially 
salvageable.13 Occlusion of the middle cerebral artery causes the blood flow of 
the core region to reduce below 10ml/100gm/min, which causes rapid necrosis 
of this region. The region surrounding the core region is the ischaemic 
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penumbra, where a blood supply of 10-20ml/100gm/min is supported by the 
collaterals.9  
           Within this ischaemic penumbra, majority of the ischaemic cascade takes 
place and that too within the first two hours of the onset of focal ischaemia.21 
The ischaemic penumbra is functionally impaired tissue. It is viable upto 
48hours after the onset of stroke. The penumbra can be saved by timely 
intervention by reperfusion with thrombolytics or attenuating the ischaemic 
cascade with neuroprotective agents. Otherwise, the metabolic and 
neurochemical consequences of ischaemia causes the penumbra tissue to 
become necrosed.22 
 The main aim of treatment is in improving the disparity between the 
energy supply and demand of the brain, thereby reducing the neuronal damage. 
This is done by supplying alternative metabolic substrates, restoring local blood 
flow, by reducing the neuronal metabolism, protecting against the toxic effects 
of the ischaemic cascade. Thus, improving the overall metabolic environment.10 
  Only a few treatment modalities are available for saving the ischaemic 
penumbra region. Current therapies include intravenous thrombolysis with 
tissue plasminogen activator, intraarterial fibrinolysis, mechanical removal, 
aspirin and moderate hypothermia (33 degree celsius) for cardiac arrest and 
decompressive hemicraniectomy for ischaemic stroke.  
18 
 
STROKE MIMICS 
• Seizures 
• Migraine 
• Hypoglycaemia 
• Syncope 
• Hypoglycaemia 
• Herpes simplex encephalitis 
• Central nervous system tumors 
• Drug overdose 
• Subdural hematoma 
• Conversion syndrome 
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VITAMIN D 
           Vitamin D has been traditionally known as the ‘sunshine vitamin’ or 
‘anti ricketic factor’. It is unique because it is the only endogenously 
synthesized vitamin that also acts as a hormone. Besides its main role in 
calcium homeostasis and bone metabolism, the vitamin D endocrine system is 
found to have a wide range of fundamental biologic functions in inhibition of 
cell growth, immunomodulation and cell differentiation.23-25  
SYNTHESIS AND METABOLISM OF VITAMIN D 
 Vitamin D is a secosteroid. It is one of the fat soluble vitamins. The main 
precursors of Vitamin D are Vitamin D2 (ergocalciferol) and Vitamin D3 
(cholecalciferol).26 
 In the skin, 7-dehydrocholesterol is converted to previtamin D3. This is 
done by exposure to Ultraviolet B rays (290-320nm wavelength). This is then 
converted to Vitamin D. Major portion of circulating 25 hydroxy Vitamin D 
(40-50%) is derived from skin. Vitamin D2 is obtained from diet and also 
formed in plants. 
 In the liver, 25 hydroxylase enzyme acts on Vitamin D2 and D3 and 
converts them into 25-hydroxy vitamin D (calcidiol). In the kidneys, 1Ω 
hydroxylase acts on 25-hydroxy vitamin D to form biologically active 1,25-
dihydroxy Vitamin D (calcitriol). 
20 
 
 
 
 
MECHANISM  OF  ACTION 
The component circulating in blood is 25 hydroxy Vitamin D. The active 
component, 1,25hydroxy vitamin D (Calcitriol) is transported in the blood to 
many target organs by Vitamin D Binding Protein (VDBP). Calcitriol acts 
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through the Vitamin D receptors (VDR). Vitamin D receptors belong to the 
nuclear receptor superfamily. After activation, the Vitamin D receptor dimerizes 
with Retinoid X Receptor (RXR) and binds to Vitamin D responsive elements 
which regulate the transcription of various genes in the target cells. 
The control of transcription requires recruitment of additional co-
regulators that may be either stimulatory(co-activators) or inhibitory (co-
suppressors). Certain genes are selective for their co-regulators. Inhibitors of 
transcription and translation can block these genomic responses. 
Around 37 different cell types and more than 500 genes have been 
identified and found to express Vitamin D receptor. Almost all cells in the body 
have Vitamin D receptor. Vitamin D regulates around 10% of the human 
genome. Vitamin D has so many pleiotropic actions because of this ubiquitous 
nature of Vitamin D receptor. 
CHEMICAL MESSENGER 
 1,25 dihydroxy vitamin D serves as a chemical messenger that transmits 
rapid responses and signals(eg. opening of ion channels). A variety of receptors 
mediate rapid responses. These receptors are associated with plasma membrane 
or its caveolae components. Caveolae are flask shaped membrane invaginations 
that are rich in cholestrol and sphingolipids.  
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Examples of rapid responses include secretion of insulin by pancreatic 
beta cells, intestinal absorption of calcium, rapid migration of endothelial cells 
and opening of voltage gated calcium and chloride channels of osteoblasts. 
Individual tissues produce their own Vitamin D3 in a tissue specific fashion. 
This ability explains how Vitamin D regulates selective functions in many 
tissues. 
SOURCES OF VITAMIN D 
SUNLIGHT 
 Sunlight is the main natural source of ultraviolet B rays. 20-30 minutes of 
sunlight exposure, 2-3 times a week, between 10am and 3pm is considered 
sufficient. Vitamin D excess due to UVB exposure doesnot occur because 
excess UVB rays convert Vitamin D3 into tachysterol and lumisterol, which are 
inactive metabolites. 3000IU of Vitamin D3 is provided by 0.5MED of UVB 
rays. 
 UVB rays are reduced by 60% by shade and severe pollution27. These 
rays donot penetrate glass, hence sunlight exposure indoors is of no use.27 More 
active Vitamin D is provided by sunlight than any other source. 
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FOOD27 
 Cod liver oil and oily fish are important sources of Vitamin D3. 
Generally vegetables are a poor source and hence food fortification programmes 
play a significant role in vegetarian diet. 
Cod liver oil (1 tsp) 400-1000 IU of Vitamin D3 
Salmon Fish (100gm) 600-1000 IU of Vitamin D3 
Tuna Fish (100 gm)   230 IU of Vitamin D3 
Mackerel Fish (100gm) 250 IU of Vitamin D3 
Egg yolk   20 IU of Vitamin D3 
SUPPLEMENTS 
 Vitamin D3 (cholecalciferol) and Vitamin D2 (ergocalciferol) are 
available as supplements. Among the two, most effective is Vitamin D3. 
VITAMIN D DEFICIENCY (HYPOVITAMINOSIS D) 
 There are many guidelines that define cut off values to assess Vitamin D 
deficiency. Recent consensus suggests that serum 25-hydroxy                 
Vitamin D > 30ng/ml as the cut off value because this is the lower limit 
(threshold) at which optimum calcium absorption occurs and parathormone 
secretion is induced.28 
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25 HYDROXY VITAMIN D – REFERENCE RANGE29 
• <10 ng/ml – Vitamin D Deficiency 
• 10.1-30 ng/ml – Vitamin D Insufficiency 
• 30.1-100 ng/ml – Normal value (sufficient) 
• >100 ng/ml – Vitamin D intoxication 
CAUSES OF VITAMIN D DEFICIENCY 
REDUCED SKIN SYNTHESIS 
• Skin pigmentation, sunscreen use, obesity and ageing reduce UVB 
related synthesis of Vitamin D from skin. 
• Latitude, time of the day and season also determine the production of 
Vitamin D from skin. 
• Elderly persons spend less time outdoors and have reduced                   
7- dehydrocholestrol as well. 
• More melanin is present in dark skinned individuals which competes 
with 7 dehydrocholestrol for absorption of UVB rays. 
• UV rays will be blocked by sunscreens with a sun protection factor 
(SPF) of 8 or more. 
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INADEQUATE  DIETARY  INTAKE 
• Elderly and children are especially susceptible. 
• Human breast milk is a poor source of Vitamin D, hence infants are also 
more prone for Vitamin D deficiency. 
REDUCED  BIOAVAILABILITY 
• Malabsorption disorders30 
• Liver Failure – impaired synthesis of 25 hydroxy Vitamin D 
• Renal Failure – impaired 1α hydroxylase activity 
• Obesity – Vitamin D is sequestrated in body fat 
• Drug interactions – Glucocorticoids, Rifampicin, Antiepileptics 
REDUCED SYNTHESIS OF ACTIVE VITAMIN D 
• Hyperphosphatemia increases fibroblast growth factor (FGF-23) which 
decreases 1α hydroxylase activity31. 
• Chronic kidney disease 
INCREASED LOSS OF 25HYDROXY VITAMIN D 
• Nephrotic syndrome – urinary loss of 25 hydroxy Vitamin D bound to 
Vitamin D binding protein. 
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INHERITED DISORDERS 
• Vitamin D dependent rickets 
• Hypophosphatemic rickets – autosomal dominant and X-linked 
• Vitamin D resistant rickets 
ACQUIRED DISORDERS 
• Hyperthyroidism – increased metabolism of 25 hydroxy Vitamin D 
• Primary hyperparathyroidism 
• Tumor induced osteomalacia – tumor secretion of FGF 23 
• Granulomatous diseases like tuberculosis, sarcoidosis and few types of 
lymphomas. 
PREVALENCE OF VITAMIN D DEFICIENCY 
GLOBAL BURDEN 
 Worldwide, one billion people are estimated to be Vitamin D deficient. 
The World Health Organisation, after a meta analysis, stated that 50-80 % of the 
population is Vitamin D insufficient.29 Vitamin D insufficiency constitutes 9.4% 
of the global disease burden.27 Worldwide, approximately 3.3billion DALYs are 
lost from bone disease due to Vitamin D deficiency.27 
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VITAMIN D DEFICIENCY – INDIAN SCENARIO32 
 Previously , there was a general disbelief that because India is near the 
equator and receives ample sunshine, Vitamin D deficiency was not prevalent in 
India. But recent data has proved approximately 50-90% prevalence of Vitamin 
D deficiency.32  
A study done by Goswami et al in New Delhi33, India in the year 2000 
showed that 90% of people in New Delhi are Vitamin D insufficient. 
Subsequent studies in urban and rural areas have shown widespread Vitamin D 
deficiency in Indians, irrespective of age and sex.32 
 In one of the recent studies, Ritu G et al37 showed that 70% of Indians 
have Vitamin D deficiency. They suggested food fortification as a must in all 
parts of India. 
Several factors contribute to this high prevalence –  
1. Calcium and Vitamin D are low in diet, especially in vegetarians. 
2. Less time spent outdoors as a result of urbanization. 
3. High fibre content, phytates and phosphates in diet. 
4. Outdoor exposure to sunlight is reduced by humid and sultry climate. 
5. Darker skin pigmentation 
6. Ultraviolet rays are hampered by increased pollution. 
7. Muslim customs like Burqa/Pardah. 
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8. Lack of vitamin D food fortification programmes. 
9. Vitamin D deficiency is aggravated in the mother and foetus by repeated 
and unspaced pregnancies. 
10. Skin disorders, liver, kidney, alcoholics, genetic factors, inflammatory 
rheumatological conditions and malabsorption disorders can lead to 
Vitamin D deficiency. 
VITAMIN D DEFICIENCY AND CLINICAL DISEASE STATES  
SYMPTOMS OF VITAMIN D DEFICIENCY 
           Previously,Vitamin D deficiency was thought to be usually 
asymptomatic but now it is accepted as an important global health problem. It is 
associated with multiple non-specific complaints such as32 
• Fatigue, generalised myalgia and weakness, muscle cramps 
• Weight gain, sleeplessness 
• Joint pain 
• Headache 
• Poor concentration 
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DISEASES ASSOCIATED WITH VITAMIN D DEFICIENCY 
• Rickets and osteomalacia 
• Malignancy 
• Osteoporosis and osteopenia 
• Systemic hypertension 
• Diabetes mellitus 
• Cardiovascular diseases 
• Obesity 
• Metabolic syndrome 
• Autoimmune diseases, Multiple sclerosis 
• Parkinsons disease, Alzheimers disease 
• Rheumatoid arthritis, Osteoarthritis 
• Fibromyalgia, Chronic fatigue syndrome 
• Depression, Seasonal affect disorder 
• Cerebrovascular accident (stroke) 
VITAMIN D REQUIREMENTS AND SUPPLEMENTATION 
• The FAO/WHO Expert Consultation states that the most physiologically 
relevant and efficient way of acquiring vitamin D, in most locations in the 
world around the equator (between latitudes 42 N and 42 S) is to 
synthesize it endogenously from skin from 7-dehydrocholesterol present 
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in the subcutaneous fat through a minimum of 30 minutes of skin 
exposure (without sunscreen) of the arms and face to the mid-day sun.34 
• Vitamin D synthesized in the skin lasts two times longer in the body as 
compared to supplemental/ ingested doses. It has been concluded from 
the experimental data that exposure of the body in a bathing suit (almost 
100% of body surface area) to sunlight that causes slight pinkness of the 
skin (1 MED -minimal erythemal dose) is equivalent to ingesting 
approximately 20,000 IU of vitamin D orally. Therefore, exposure of 6% 
of the body to 1 MED is equivalent to taking about 600 and 1,000 IU of 
vitamin D.35 
• Applying the rule of nines Burns chart, exposure of both forearms and the 
face is equivalent to exposing 12% of body surface area. For Caucasian 
skin (type 2 or 3), exposing the face, arms and legs for a period equal to 
25% of the time that it would take to cause 1 MED, two to three times a 
week can meet the body’s vitamin D requirement while minimizing sun 
damage (“ Holick’s rule”).36  
• Asians have darker skin (type V) and therefore, with the same amount of 
MED, they would require a longer duration of sun exposure than their 
light-skinned counterparts to synthesis comparable amounts of vitamin 
D.35 The time required to obtain the recommended UV dose for adequate 
vitamin D synthesis is “1 Standard Vitamin D Dose” (SDD). Throughout 
the year 1 SDD for skin type V (Asians) is 10-45 minutes at solar noon, 
31 
 
with longer durations in winter. SDD for skin types is collected on MED. 
Clouds, aerosols and dense ozone can reduce vitamin D synthesis and 
force “Vitamin D winter” even at the equator. India is located at between 
8.4 and 37.6°N.  
• In a study from South India (Tirupati)38-40 using ‘in vitro’ ampoule 
model with precursors of Vitamin D (7 Dehydrocholesterol), when 
exposed to sunlight, converted to active vitamin D best between 11 a.m. 
to 2 p.m (mid-day sun) . The median percentage conversion of 7-DHC to 
previtamin D and its photoproducts and percentage of previtamin 3D and 
vitamin D formed were 11.5% and 10.2%, respectively at a solar zenith 
angle of 36.8° at 12:30 p.m. From the various studies in the literature, it 
would appear that the 25 (OH)D levels in South Indian subjects are 
relatively higher than in subjects in North India. There is a strong inverse 
correlation between the 25 (OH)D levels and latitude (r = -0.48; p < 
0.0001), clearly establishing the relationship between closeness to the 
equator (smaller zenith angle) and natural Vitamin D synthesis .  
• Studies from Pune40 (latitude 18.31°N and longitude 73.55 E) have 
shown that toddlers exposed to sunlight (playing outside) for more than 
30 min a day, exposing more than 40% of their body surface area, had a 
normal vitamin D status (M: 36.6 ng/ml and F: 27.1 ng/ml), three times 
more than the toddlers who were indoors for most part of the day (M: 
12.8 ng/ml and F: 8.4 ng/ml) .  
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• A study in toddlers in Delhi slums41 (latitude 28.35 N and longitude 
71.12 E) demonstrated that those who were exposed to sunlight had better 
vitamin D levels (~ 25 ng/ml) as compared to those who were not ( ~ 
8ng/ml). Interestingly, authors of this study also identified (albeit 
retrospectively) that families whose toddlers were exposed to sunlight 
had been given educational material by the local healthcare workers 
explaining the benefits of exposure to sunlight . 
VITAMIN D AND AGE VARIATION 
VITAMIN D STATUS IN ADULTS 
Recent studies from India have shown high prevalence of vitamin D 
deficiency in both rural and urban populations of adults, in north as well as 
south India. However, the only large population survey41 of vitamin D and 
dietary calcium, done by Harinarayan et al39, is from rural and urban south 
India . It has been shown in population surveys from South India (Tirupati 
latitude 13.40 N and longitude 77.2 E) that even rural adult agricultural 
labourers, despite being exposed to sunlight for more than 4 hours with at least 
35% of their body surface area exposed to sunlight, still show vitamin D 
deficiency. No difference of Vitamin D status among the varous age groups was 
found. 
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NEWBORNS AND VITAMIN D DEFICIENCY 
 More than 3000 genes that affect fetal development42 are induced by 
Vitamin D and thus a critical role is played by Vitamin D in brain development 
and function43. Normal transcriptional activity in the brain can be ensured by 
adequate Vitamin D levels in utero. 
 Vitamin D deficiency is seen in 84% of pregnant women in India, which 
correlates with reduced serum 25 hydroxy Vitamin D levels in their newborns. 
Intrauterine development and postnatal skeletal growth were reduced in their  
off springs.44 Human breast milk has very little vitamin D and so exclusively 
breast fed infants have increased risk of rickets. Vitamin D deficiency  
compromises the skeletal built from birth and continues into childhood, 
eventually compromising adult height. 
VITAMIN D STATUS IN CHILDREN 
Studies show that 60-80% of the variability in bone mass is due to genetic 
factors, with the rest being attributable to nutrition, lifestyle, physical activity 
and hormonal factors. Approximately 40-50% of total skeletal mass is 
accumulated during childhood and adolescence. It is during this period that 
calcium and vitamin D nutrition and non pharmacologic strategies should be 
adopted to have the maximum impact on peak bone mass.  
The mean serum concentrations of 25(OH)D reported in children and 
adolescents from urban northern India were 11.8 ± 7.2 ng/ml and 13.84 ± 6.97 
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ng/ml, respectively . These were lower than those reported in children from 
southern India . The mean 25(OH)Dconcentrations in adolescents in urban and 
rural Andhra Pradesh were 17 ng/ml and 18 ng/ml, respectively.41  
An objective evaluation of the association between nutrition and life style 
clearly revealed a significant correlation between serum 25(OH)D and 
estimated sun exposure (r=0.185, p<0.001) and percentage body surface area 
exposed (r=0.146, p<0.004) but not socio-economic status, suggesting that life-
style related factors contribute significantly to the low vitamin D status of 
apparently healthy school girls.41 The functional significance of low serum 
25(OH)D in Indian children is reflected in their serum PTH values. 
VITAMIN D STATUS IN REPRODUCTIVE AGE GROUP 
Available data from population surveys indicate that the Vitamin D status 
of women in reproductive age groups is uniformly low in both North and South 
India . Low vitamin D status and low dietary calcium in reproductive-age 
women, coupled with unplanned and unspaced pregnancies, lead to decrease in 
bone mineral density and consequent low peak bone mass, rendering these 
women vulnerable to postmenopausal osteoporotic fractures later in life. 
VITAMIN D STATUS IN POSTMENOPAUSAL WOMEN 
Evaluation of daily dietary calcium intake, phytate-to-calcium ratio,and 
bone mineral parameters in South Indian, postmenopausal women (n=164) 
showed that their dietary intake of calcium was low compared with the 
Recommended Dietary Allowance for Indians. Around 85% had either 
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insufficiency or deficiency of 25 hydroxy Vitamin D. Parathormone and serum 
alkaline phosphatase levels were significantly higher in patients with 
25(OH)D deficiency (p<0.05) as compared to those with normal 25(OH)D 
levels. There was a negative correlation between 25(OH)D and Parathormone 
(p<0.007) and Serum Alkaline Phosphatase ( p<0.001).45 
 The study concluded that the quality of the diet has to be improved, with 
enrichment/ supplementation of calcium and vitamin D in order to suppress 
secondary hyperparathyroidism-induced bone loss and risk of fractures in post-
menopausal women . In another study of vitamin D status in postmenopausal 
women from south India, it was found that vitamin D deficiency coexists with 
low bone mineral density (BMD).46 This points to the need to document serum 
25(OH)D levels in women with low BMD.  
Calcium and vitamin D supplementation should form part of therapy in 
postmenopausal women . Similar findings were reported from studies carried 
out in North India. 
VITAMIN D AND GENDER VARIATION 
 In a study conducted by Johnson et al47, it was found that there was 
significant difference in Vitamin D levels between males and females with a 
mean Vitamin D level of 21ng/ml among males and 22.4ng/ml among females 
in Europe. The reason for the gender difference could not be ascertained from 
the study. Generally men are more exposed to sunlight than females. So they 
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must have more Vitamin D than women. But this study,gave results against the 
general consensus. 
VITAMIN D AND SMOKING 
 In a study conducted by Eugenia Cutillas et al48, it was found that 
smoking causes significant reduction in Vitamin D levels. This study was done 
in Europe in 2009. It is mentioned that smoking reduces Vitamin D levels by 
reducing the formation of 25 hydroxy vitamin D. Few other speculations have 
been made but none have been proved. 
OBESITY AND VITAMIN D 
Obese individuals need 2 to 3 times more vitamin D per day (that is, 
3000 to 6000 IU) to compensate for the impairment in ability to maintain       
25- hydroxy Vitamin D levels in the blood. With deficiency of dietary calcium, 
there is an up to five-fold increase in fatty acid synthetase, an enzyme that 
converts calories into fat. The presence of sufficiently high levels of calcium 
and adequate vitamin D inhibits the enzyme.  
In obese persons, vitamin D supplementation may improve muscle 
strength, reduce the occurrence of aches and pains, and enable increased 
physical activity. It may also help in weight reduction and improve insulin 
metabolism. It is important to remember that drugs used for reducing fat, such 
as orlistat inhibit not only the absorption of fat but also that of vitamin D. 
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Studies done by Carlin et al in 2006 and Aasheim et al in 200848, in 
Northern America  have shown a 40% higher incidence of Vitamin D deficiency 
among people with obesity. Obesity was classified based on the Body Mass 
Index in all these studies. 
VITAMIN D AND STROKE 
Pathophysiological mechanisms remain speculative, but several possible 
biological mechanisms might explain the association of low 25 hydroxy 
Vitamin D with stroke. 
• Lower vitamin D levels can induce brain damage and cognitive and  
functional impairment.  
• Vitamin D deficiency has been associated with morphological brain  
changes, motor impairments, and memory and learning impairments in animal 
models.  
• Additionally, numerous further studies have indicated that vitamin D  
deficiency is associated with accelerated bone resorption and reduced bone 
mineral density in stroke patients.  
• In addition, low 25(OH)D levels may contribute to pro-atherosclerotic 
changes of vascular smooth muscle cells, endothelial dysfunction and increased 
macrophage to foam cell formation.  
• High dose oral vitamin D supplementation produced short-term  
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improvement in endothelial function in stroke patients with wellcontrolled 
baseline blood pressure.  
• Finally, low 25(OH)D levels are known to influence macrophage and  
lymphocyte activity in atherosclerotic plaques and to promote chronic 
inflammation in the artery wall. Various studies suggest that vitamin D may 
exert anti-inflammatory effects. Reduced 25(OH)D levels might be associated 
with overall increased inflammatory activity. 
In a study conducted by Kenneth et al49 in 2005, 77% of patients with 
acute ischaemic stroke had Vitamin D insufficiency.This was one of the pioneer 
studies involving Vitamin D conducted in United States of America. They 
evaluated the levels of 25 hydroxy Vitamin D at the onset of stroke and 30 days 
later and found significant Vitamin D deficiency at the onset of stroke and 
during followup studies. 
In a study conducted by Stefan Pilz et al50 from 1997-2000, it was found 
that lower Vitamin D levels have independent predictive value in fatal strokes 
and Vitamin D supplementation can prevent fatal strokes. They found 58% 
prevalence of Vitamin D deficiency in stroke patients. 
In a recent study conducted by Tu WJ et al in China51 from 2010 to 
2012, it was found that the mean 25 hydroxy Vitamin D levels in patients with 
acute ischaemic stroke was 10.2–18.9ng/ml and in normal controls it was 17.5-
22.9ng/ml. They also concluded that Vitamin D levels is an independent 
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predictor of mortality after acute ischaemic stroke within 90 days of stroke 
episode. 
In 2013, the Vitamin D council,52 in its statement declared that Vitamin 
D deficiency is an important global problem with significant association to 
stroke. It suggested many groups to do further studies into the association 
between Vitamin D and stroke and the pathogenesis behind it. 
The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study53 
conducted from 1997 to 2000 found that over a period of 7.7 yrs of followup 
after acute stroke, 92% patients had below normal Vitamin D levels. But 
whether this was the cause for stroke or the after effect of stroke could not be 
predicted from this study. But they suggested a definite link between acute 
ischaemic stroke and Vitamin D. 
NHANES study(National Health and Nutrition Examination 
Survey)54 showed that over a median of 14years, whites with low vitamin D 
levels had double risk of stroke compared to those having higher levels of 
vitamin D.  
A study done by Deidre A de Silva et al55, showed that in Asian 
population, 95% of acute ischaemic stroke patients had below normal Vitamin 
D compared to 84% in controls with 39% of cases and 20% of controls having 
Vitamin D deficiency.  
40 
 
VITAMIN D DEFICIENCY AND BONE HEALTH  
 Vitamin D plays a pivotal role in maintaining serum calcium and 
phosphorous. Without vitamin D, only 10-15% of dietary calcium and 60% of 
phosphorous is absorbed.12-14 Thus, Vitamin D is an integral part of skeletal 
mineralization. 
 Vitamin D deficiency causes secondary hypoparathyroidism which leads 
to osteopenia and osteoporosis by increasing bone resorption. As a result of 
raised parathormone, phosphaturia and hypophosphataemia occur causing 
defective mineralization of bone osteoid. 
 Rickets and osteomalacia are widely prevalent in India29. Low peak bone 
mass leads to pseudofractures. On routine screening, there is wide prevalence of 
biochemical osteoporosis and osteomalacia in our population. The benefits of 
25hydroxy vitamin D on skeletal health starts from early fetal life and continues 
upto adulthood.12 
 Hollick et al, Dawson Hughes et al and many others 26 have linked low 
levels of 25 hydroxy vitamin D to fractures. Osteoarthritis of hip and knee joint 
has also been associated with vitamin D deficiency. 
 Surveys from rural south India (Tirupati) have shown that Vitamin D 
levels are higher in agricultural workers who are exposed to long hours of 
sunlight as compared to urban dwellers (24ng/ml vs 19ng/ml)39-41. Serum 
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Vitamin D levels were significantly lower than expected for the duration of 
sunlight exposure, inspite of high exposure to sunlight. Studies on dietary habits 
of this population have shown that these persons habitually consume low-
calcium, high-phytate diets. Of the daily diet of 1700 KJ/day approximately in 
these rural individuals, carbohydrates provided 75% of the total energy intake,  
fat 5%,proteins 10%, vegetables 5%, and milk and milk products 5%. The 
carbohydrate sources were cereals [Rice – 60% and Ragi-40%]. Animal sources 
of protein were consumed approximately once in 2 weeks only.  
 In the diets of urban individuals, with a total energy intake of 2200 
KJ/day approximately, carbohydrates provided 55% of the total energy intake, 
proteins 10%, fat 10%, vegetables 10%, and milk and milk products 15%. The 
carbohydrate sources were primarily cereals (rice 50%, wheat 25%, and ragi 
25%). Animal sources of protein were consumed only once a week. There was 
no other source of calcium or any other mineral in either of the groups. Milk in 
India is not fortified with calcium or vitamin D. 
The daily dietary calcium intake reported in both rural and urban 
populations in the Tirupati study were low (mean + SEM: rural 264 ± 1.94; 
urban 354 ± 5 mg/day) as compared to the Recommended Daily/Dietary 
Allowance (RDA) for Indians(800mg/day). The consumption of Ragi (rich in 
phytates) by the rural population retards the absorption of calcium from the gut. 
Similar calcium-deficient diets have been reported in other Indian studies as 
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well . The average dietary calcium intake in India seems to be 430 ± 180 
mg/day in children and 560 ± 310 mg/day in adults . All studies have uniformly 
documented low dietary calcium intake as compared to the ICMR’s RDA 
norms. 
 Low calcium intake increases parathyroid hormone (PTH), which in turn 
increases conversion of 25(OH)D to 1,25-dihydroxyvitamin D. In addition, 
1,25-dihydroxyvitamin D induces its own destruction by increasing 24-
hydroxylase . This probably explains the low 25hydroxy vitamin D 
concentrations in persons on a high-phytate or a low-calcium diet. It is, 
therefore, essential that calcium supplementation should be made an integral 
part of vitamin D supplementation therapy in India. 
VITAMIN D DEFICIENCY AND TYPE 2 DIABETES MELLITUS 
 The current prevalence of Type 2 Diabetes mellitus is high both in urban 
and rural India.56 By the year 2030, it is estimated that India would have the 
maximum number of diabetics in the world.57 
 A study done by Pittas et al58 has shown that increased risk of type 2 
Diabetes mellitus when serum 25 hydroxy Vitamin D levels fall below 30 
ng/ml. It has also been proven that glycemic status worsens in Winter which is 
associated with reduced Vitamin D levels. 
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 Vitamin D receptors are present in the pancreas and it also has 1α 
hydroxylase activity. Hence it can convert 25 hydroxy Vitamin D into 1,25 
dihydroxy Vitamin D in a minor way and act in a paracrine or autocrine fashion. 
In a recent study, one group has shown that optimal treatment with vitamin D as 
per current Endocrine Society guidelines and supplementation with calcium 
improves pancreatic beta cell function in normoglycaemic subjects with vitamin 
D deficiency. 
Mechanisms by which Vitamin D prevents Diabetes mellitus: 
1. Enhances insulin release by improving beta cell function, either directly or 
by increasing the intracellular ionised calcium level. 
2. Inhibits beta cell apoptosis57 
3. Increases the sensitivity of calcium dependent pathways in target cells that 
enhance glucose utilisation 
4. Increases the expression of insulin receptors, thus increasing insulin 
sensitivity. 
VITAMIN D DEFICIENCY AND SYSTEMIC HYPERTENSION 
 Pfeifer et al59 showed a  9% fall in systolic blood pressure after 
supplementing 800 IU of Vitamin D. In another study, in patients exposed to 
UVB rays for 3 months thrice a week, there was 180% increase in Vitamin D 
levels and 6 mmHg reduction in both systolic and diastolic BP. 
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 On the contrary, Forman et al60 showed no correlation between 
hypertension and Vitamin D supplementation. 
Mechanisms implicated are: 
• Direct effect on endothelial cells 
• Regulation of calcium metabolism 
• Suppression of Renin Angiotensin Aldosterone axis 
• Norepinephrine and Angiotensin II play a main role in the pathogenesis 
of hypertension. Vitamin D has a role in the regulation of these. 
VITAMIN D IN CHRONIC RENAL FAILURE 
 Patients with chronic kidney disease treated with Vitamin D have shown 
a fall in death rates by 20%.49Antiproteinuric effect of Vitamin D has also been 
demonstrated.49A study done by Williams et al61 found that patients with 
chronic renal failure had severe Vitamin D deficiency and Vitamin D 
supplementation over a 3 month period had significant reduction in morbidity in 
these patients. Low vitamin D also leads to high incidence of cardiovascular 
events in chronic renal failure patients. 
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VITAMIN D AND ATHEROSCLEROSIS 
• Parathormone promotes the formation of intra-arterial plaque, thus 
increasing the risk of atherosclerosis. Hence calcification and stenosis in the 
blood vessels is reduced by suppressing parathormone activity. 
• Vitamin D maintains normal vascular tone by promoting nitric oxide  
production, suppressing platelet aggregation and thrombogenic activity. 
Vitamin D governs many bone proteins like matrix G1a protein and 
osteoprotegerin which are present in the blood vessel wall. In case of vitamin D 
deficiency, these proteins cause calcification of vessels. 
• Vitamin D has anti-inflammatory activity. It affects macrophages and  
dendritic cells, reducing foamy macrophages and suppressing cholestrol uptake. 
• Moreover, few cardiac drugs increase Vitamin D levels. Vitamin D levels  
are increased by 70% after 1 year of treatment with statins. Drugs like beta 
blockers, aspirin, thiazide diuretics,etc. have shown to enhance Vitamin D 
activity.  
• Vitamin D reduces risk of diabetes mellitus and hypertension, thereby  
reduces the risk of atherosclerosis.  
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VITAMIN D AND CORONARY ARTERY DISEASE 
 In a large randomized trial by Wang et al62, the relative risk of 
developing myocardial infarction was 3 times more in individuals with Vitamin 
D deficiency when compared with individuals with normal Vitamin D levels. 
Vitamin D acts mainly by gene transcription and maintaining calcium 
homeostasis to prevent cardiovascular diseases and its risk factors.   
Mechanisms for cardiovascular protective effect include- 
• Protective action on the endothelium 
• Inhibition of renin 
• Regulation of parathormone 
• Anti- inflammatory action 
• Plaque stability 
• Preventing cardiac hypertrophy 
• Reduced cardiac contractility 
• Reduced risk of arrythmias 
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VITAMIN D AND DYSLIPIDEMIA 
 A study done by Chaudhuri et al71 in 2013 in India showed that people 
with Vitamin D deficiency have dyslipidemia, as shown by increased LDL 
cholestrol, decreased HDL cholestrol,increased total cholestrol and increased 
triglycerides. Significant association was shown when the vitamin D levels were 
less than 20ng/ml. 
 Another study done by Zittermann et al72 in Europe also found a 
significant association between Vitamin D and dyslipidemia. The mechanisms 
are mostly speculative with none being proved scientifically. 
MUSCLE STRENGTH AND VITAMIN D 
Muscle strength plays an important role in determining risk for falls, 
which result in fractures and other injuries. Muscle wasting is a multifactorial 
process involving intrinsic and extrinsic alterations. There are studies to show 
moderate inverse relationship between vitamin D status and muscle strength .  
Randomized controlled trials (RCTs) of the effect of vitamin D/calcium 
supplementation on skeletal muscle strength have not shown positive effects in 
the elderly. Oral cholecalciferol/calcium supplementation in the dose/schedule 
that is generally used for increasing and maintaining serum 25(OH)D did not 
lead to improved skeletal muscle strength in young women. 
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SKIN DISEASES AND VITAMIN D  
Psoriasis is a semi-autoimmune disease which affects approximately 50 
million people worldwide. It affects mostly adults and is characterized by raised 
patches of thick, red skin covered with silvery scales. These patches are 
sometimes called plaques, which generally itch and may burn. Under normal 
circumstances, skin cells grow, divide and replace themselves in an orderly 
fashion. But in psoriasis, cells start reproducing in an uncontrolled manner.  
Psoriatic skin may “turn over” (be replaced) in as little as four days as 
compared to normal skin which turns over in twenty-one days. Local 
application of skin ointment of activated vitamin D (calcitriol) dramatically 
reduces the symptoms of psoriasis. 
VITAMIN D DEFICIENCY AND AUTOIMMUNITY 
 Vitamin D deficiency has been linked to many autoimmune diseases like 
Type 1 diabetes mellitus, multiple sclerosis, rheumatoid arthritis and 
inflammatory bowel disease. This is attributed to the fact that Vitamin D 
receptors are present on monocytes, dendritic cells, macrophages, WBCs, CD4 
and CD8 T cells. Thus, the immune system of the body is also affected by 
Vitamin D. Cytokine production and T cell proliferation are inhibited by 
Vitamin D.63 
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 Epidemiological data show correlation between the seasonal variation in 
the onset of these autoimmune diseases with vitamin D deficiency.63 Vitamin D 
improves and prevents Multiple sclerosis by increasing TGF β levels.49 
VITAMIN D DEFICIENCY AND TUBERCULOSIS 
 Before the advent of anti tubercular drugs, high doses of Vitamin D and 
cod liver oil were used to treat tuberculosis in the 18th  and 19th century. This 
was done on the basis that Vitamin D would calcify the tuberculous lesions.64 
Vitamin D deficiency is an independent risk factor for Tuberculosis in South 
Asians.64 This is mainly because Vitamin D promotes killing of the intracellular 
mycobacteria by increasing cathelicidin in the macrophages. 
Patients with chronic granulomatous diseases such as sarcoidosis, 
and those with tuberculosis or fungal infections are at risk of vitamin D 
deficiency, because their immune systems are activating the vitamin D. They 
need to be treated for vitamin D deficiency but should receive much smaller 
doses of vitamin D than patients who are otherwise normal and are being treated 
for vitamin D deficiency alone. Otherwise they may develop hypercalcemia and 
hypercalcuria. The 25(OH)D levels in such patients should be maintained 
between 20-30 ng/ml. 
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VITAMIN D DEFICIENCY AND MALIGNANCY 
 Certain malignancies like Hodgkins Lymphoma, colon, prostrate, 
ovarian, pancreatic, breast carcinoma and few others are more prevalent among 
people living in higher latitudes. Low Vitamin D in these regions is attributed as 
one of the reasons. Vitamin D induces apoptosis, regulates cell cycle and cell 
differentiation. It inhibits tumor growth and metastasis. 30-50% reduction in 
the risk of malignancy after Vitamin D supplementation as been shown by few 
studies.65 
Another study showed the beneficial effect of sunlight on both breast 
cancer and prostate cancer . Cancers of the digestive tract (colon, rectum, 
mouth, esophagus, stomach and pancreas) are also associated with low 
25(OH)D levels .  
Ethnicity may also have a role to play. Vitamin D deficiency was found 
to be more prevalent and pronounced in African Americans than in Caucasian 
Americans . It has been reported that, after adjusting for multiple dietary, 
lifestyle and medical risk factors, African American men were at 32% greater 
risk of total cancers and especially cancers of digestive tract than their 
Caucasian counterparts.  
About 75% of women with breast cancer who are vitamin D deficient at 
diagnosis die from the disease while mortality risk is lower in women with 
normal vitamin D levels at diagnosis.  
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Data analysis from the National Health and Nutrition Examination 
Survey [NHANES I]67 in 1999 demonstrated that increased exposure to 
sunlight could, by itself, potentially reduce the incidence and death rate of 
breast cancer in the Unites States by 35 to 75% .  
Results pooled from the Harvard Nurses Health study and St. Georges 
Hospital study in London66 showed that patients with high 25 hydroxy 
Vitamin D  levels had the lowest risk of breast cancer . 
Prostate cancer is fatal in about 25% of the cases. It has been reported 
that the risk of developing prostate cancer is inversely related to the level of 
exposure to sunlight . Men with prostate cancer who received 2000 IU of 
vitamin D daily were shown to have a 50% reduction in risk as measured in 
terms of the levels of prostatic specific antigen (PSA), an indicator of cancer 
activity. Those living at higher altitudes are generally at increased risk of 
developing cancer66. 
Studies from Creigton University67 reported that postmenopausal 
women who took 1500 mg/day of calcium and 1100 IU/day of vitamin D for 
four years had a 60% reduction in the risk of developing all cancers as 
compared to placebo group .  
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ROLE OF VITAMIN D IN OTHER DISEASES 
Crohn’s disease affects the proximal small intestine and hampers 
25(OH)D absorption. Recent advances in understanding the pathophysiology of 
Crohn’s disease have revealed the so-called north– south gradient of Crohn’s 
disease . In a genetically predisposed individual, Crohn’s disease occurs 
because of the dysregulated response of the mucosal immune system to 
intraluminal antigens of bacterial origin. A normally functioning mucosal 
immune system inhibits immune response to luminal antigens and suppresses 
gut inflammation (immune tolerance).  
The mechanism whereby exposure to sunlight is thought to exert a 
beneficial effect on intestinal inflammation may involve vitamin D. Sunlight 
and vitamin D might protect against Crohn’s disease by down-regulating the T 
helper-1 (TH1)-driven immune response. The mechanism through which 
heliotherapy (UV-B rays) induces immune suppression may include the 
induction of various TH 2 cytokines such as IL-4 and IL-1012.  
Vitamin D may be the coordinator of the cross talk between the 
immunological system in the gut and various subcellular events in bone 
formation. Approximately 10% of the population has silent Coeliac disease. 
These individuals have difficulty in absorbing fat-soluble vitamin D. Unless 
they have enough UV-B to maintain healthy vitamin D levels, they should 
receive vitamin D supplementation to maintain their 25(OH)D levels at >30 
ng/ml.  
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Cystic fibrosis leads to malabsorption of vitamin D. Patients with this 
disease require aggressive supplementation with vitamin D to maintain 
25(OH)D levels at > 30ng/ml. 
In cirrhosis of the liver when more than 80% of the liver is destroyed, 
there is decreased production of 25(OH)D and poor absorption of fat as well as 
of vitamin D. Mild to moderate malabsorption is a major cause of vitamin D 
deficiency in these patients. A similar situation prevails in primary biliary 
cirrhosis. These conditions call for aggressive treatment with vitamin D.  
 
DIAGNOSIS OF VITAMIN D DEFICIENCY 
 The most sensitive marker to assess the vitamin D status in the general 
population is 25 hydroxy Vitamin D, which is the main circulating form of 
Vitamin D. This is because it has a longer half life of around 2-3 weeks and can 
be easily measured. Moreover, clinical disease states correlate well with serum 
25 hydroxy Vitamin D levels. 
 1,25dihydroxy Vitamin D has a shorter half life of 15hrs and is easily 
affected by calcium, phosphorous and parathormone levels, hence it is a poor 
indicator of Vitamin D deficiency. Also, its levels fall only when there is severe 
Vitamin D deficiency. Usually serum calcium is found to be normal in people 
with Vitamin D deficiency due to effective compensatory mechanisms like 
increased parathormone levels. 
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METHODS TO ASSESS 25 HYDROXY VITAMIN D LEVELS 
• Ligand Binding Assays 
- Radioimmunoassay 
- Chemiluminescence assay 
- Competitive protein-binding assays 
• Liquid chromatography – tandem mass spectrometry (LC-MS/MS) 
- Accurate and precise 
- Considered the ‘Gold Standard method’ 
• High performance liquid chromatography (HPLC) 
TREATMENT OF VITAMIN D DEFICIENCY 
Dosing68 
 As per the Institute of Medicine (IOM), the level of deficiency and 
treatment with Vitamin D supplementation should be individualised. 
• 25hydroxy Vitamin D < 20ng/ml (50nmol/L) – 50,000 IU of Vitamin 
D2 or D3 orally once a week for 6-8weeks, followed by 800-1000 IU 
of Vitamin D3 daily. 
• 25hydroxy Vitamin D 20- 30 ng/ml (50 - 75 nmol/L) – 800 to 1000 IU 
of Vitamin D3 daily for 3 months 
• In infants and children with 25hydroxy Vitamin D < 20ng/ml (50 
nmol/L) – 1000 to 5000 IU of Vitamin D2 daily for 2-3 months. 
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• 1200 mg of calcium daily for postmenopausal women and 1000 mg 
daily for prmenopausal women should be supplemented along with 
Vitamin D. 
MONITORING BLOOD LEVELS 
 Blood levels of 25 hydroxy Vitamin D should be monitored every 3 
months after starting treatment and dose adjustments made accordingly. 
PREVENTION OF VITAMIN D DEFICIENCY 
 Vitamin D deficiency and its complications can be prevented by adequate 
sun exposure, fortification of foods, public awareness campaigns and adequate 
Vitamin D supplementation in vulnerable population. Vitamin D 
supplementation must be properly advised to the people and the dosing be 
adjusted according to degree of sun exposure, skin colour, diet and underlying 
medical conditions. 
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Recommended Dietary Allowances (RDAs) for Vitamin D68 
Age Male Female Pregnancy Lactation 
0-12 months 400 IU 400 IU   
1-13 yrs 600 IU 600 IU   
14-18 yrs 600 IU 600 IU 600 IU 600 IU 
19-50 yrs 600 IU 600 IU 600 IU 600 IU 
51-70 yrs 600 IU 600 IU   
>70 yrs 800 IU 800 IU   
(40 IU =  1mcg) 
 The current recommendation is to take 2000IU of Vitamin D and 1-1.5 
gm of calcium daily in order to prevent Vitamin D deficiency in the Indian 
population. 
In March 2007, a group of Vitamin D researchers published a 
controversial editorial mentioning the desirable concentration of 25 hydroxy 
Vitamin D was ≥ 30 ng/ml (≥75nmol/L).69 They told that approximately      
1700 IU/day of Vitamin D is needed to raise 25 hydroxy Vitamin D levels from 
20ng/ml to 32ng/ml. However, the FNB committee that recommended the 
Recommended Daily Allowance for Vitamin D extensively reviewed a wide 
range of articles and came to the conclusion that with the exception of measures 
related to bone health, the health relationships examined were either not 
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supported by satisfactory evidence or had a conflicting nature of evidence, 
hence specific levels of Vitamin D intake cannot be linked to any of these 
conditions. 
VITAMIN D – DRUG INTERACTIONS 
Drugs that decrease the serum levels of Vitamin D by increasing its 
metabolism 
Phenytoin, Fosphenytoin, Phenobarbitone, Carbamazepine, Non-nucleoside 
reverse transcriptase inhibitors, Rifampin, Theophylline, Cimetidine 
Decrease the intestinal absorption of Vitamin D 
Cholestyramine, Colestipol, Mineral oil, Orlistat  
Others: 
Ketoconazole – reduces serum levels of Vitamin D by inhibiting 1α hydroxylase 
enzyme 
Corticosteroids – impair Vitamin D metabolism and calcium absorption 
Thiazide diuretics and statins – increase serum Vitamin D levels 
Vitamin D toxicity – can precipitate cardiac arrythmias by causing 
hypercalcemia, especially in patients on digoxin 
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HYPERVITAMINOSIS D 
 It is extremely rare. It can result from poisoning or when Vitamin D 
deficiency is treated without monitoring serum levels. 
 Doses more than 10,000 IU/day can cause serum levels of 25 hydroxy 
Vitamin D to go above 150 ng/ml causing acute hypercalcemia and 
hyperphosphatemia. Lymphoma and primary hyperparathyroidism also can 
increase the risk of hypercalcemia in response to Vitamin D.70 
TOLERABLE UPPER INTAKE LEVEL FOR VITAMIN D70 
As per the Institute of Medicine (IOM), 
Infants: 0-6 months – 1000 IU/day 
    6-12 months – 1500 IU/day 
Children: 1-3 yrs – 2500 IU/day 
       4-8yrs – 3000 IU/day 
Adults: > 9yrs – 4000IU/day 
As per the European Food and Safety Authority ( EFSA), 
0-10yrs – 1000 IU/day 
>11yrs – 2000 IU/day 
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CLINICAL FEATURES OF HYPERVITAMINOSIS D 
• headache, dehydration, lethargy 
• constipation, loss of appetite 
• nausea, vomiting, abdominal pain 
• failure to thrive ( in children) 
• renal stones 
• polyuria, polydipsia 
• increased 1α hydroxylase activity led to premature ageing in mice 
• increased risk of vascular calcification and pancreatic cancer has been 
associated with serum levels of 25 hydroxy vitamin D > 60 ng/ml. 
MANAGEMENT OF HYPERVITAMINOSIS D 
 It needs treatment with intravenous fluids, steroids and calcium restricted 
diet. Bisphosphonates may be needed to control hypercalcemia. 
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The wide spectrum of action of Vitamin D continues to intrigue the 
scientific community. The calcemic beneficial effects of vitamin D have been 
fully established through outcome studies, and the guidelines for treatment of 
vitamin D deficiency for calcemic benefit are established. The non-calcemic 
beneficial effects are gradually becoming better understood. While we await 
guidelines for vitamin D supplementation for non-calcemic benefits, it may be 
prudent to maintain the serum 25(OH)D levels at 30 ng/ml, and also ensure a 
diet-cum-supplement calcium intake of 1 gm per day. 
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MATERIALS AND METHODOLOGY 
 
PLACE OF STUDY:  Government  Kilpauk  Medical  College & Hospital, 
                                     Chennai-600010 
STUDY DESIGN:  Observational Case- Control Study 
DURATION OF THE STUDY:  6 months 
PERIOD OF STUDY:  March 2014 to August 2014 
SAMPLE SIZE: 50 cases and 50 controls ( age and sex matched) 
COLLABORATING DEPARTMENTS:  
Department of  Neurology, Department of Biochemistry,   
Department of Radiology, Government Kilpauk Medical College 
& Hospital. 
CONFLICT OF INTEREST:  
         There was no conflict of interest. 
ETHICAL CLEARANCE:   
                   Obtained. The study protocol was approved by the Ethical  
Committee of Government Kilpauk Medical College & Hospital,Chennai-10 for 
research studies conducted in February, 2014. 
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INFORMED CONSENT:   
                    Both the case and control study groups were informed about the  
nature of the study. Members who were willing to participate in this study were 
included after getting their written informed consent. 
                     Patients who fulfil the inclusion and exclusion criteria were 
enrolled in the study.  
 
INCLUSION  CRITERIA: 
1. Patients with new onset stroke with an acute infarct on CT Brain, 
admitted in Medical Wards in Governemnt Kilpauk Medical College 
Hospital, within 7days of onset of stroke were taken as cases. 
2. Patients without stroke, who attended the Medical OPD were taken as  
Controls ( Age and sex matched). 
 
EXCLUSION  CRITERIA:             
Patients with - 
1. History of Transient Ischaemic Attacks, prior stroke 
2. Diabetes mellitus 
3. Systemic hypertension 
4. Coronary artery disease 
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5. Chronic kidney disease 
6. On drugs that affect Vitamin D metabolism  
(Anti epileptics, Steroids, Rifampin) 
7. Calcium or vitamin D supplements 
 
DATA COLLECTION: 
             A data collection form was prepared to note the Name, Age, Sex,  
Smoking, Drug Intake and other relevant history, Height and Weight of the  
cases and controls.  
               The CT Brain reports of the cases were noted. 
 
LABORATORY INVESTIGATIONS: 
• Blood samples were taken at the time of admission to measure the 
serum levels of 25 hydroxy Vitamin D level and lipid profile ( HDL cholestrol, 
LDL cholestrol, Total Cholestrol and triglycerides). 
• Serum levels of 25 hydroxy Vitamin D levels were measured by  
Chemi Luminescence Immuno Assay Technique. 
• Lipid profile was measured using enzymatic methods.  
• Tests were done in a single laboratory by the same person. Therefore no  
interpersonal error was possible. 
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NORMAL VALUE OF THE PARAMETERS: 
The normal value of the parameters assessed is listed below. 
• Vitamin D levels 
            Normal 30-100ng/ml 
            Insufficient 10-30ng/ml 
            Deficient <10ng/ml 
• Obesity- based on Body Mass Index (for Indian population) 
BMI = weight(kg)/Height2(m2) 
             Normal- 18.0-22.9 kg/m2 
             Overweight- 23.0-24.9 kg/m2  
             Obese >25 kg/m2 
• Lipid Profile - normal values (NCEP guidelines)  
          Serum triglycerides  <150mg/dl 
          LDL Cholesterol  <100mg/dl 
          HDL cholesterol  >40 mg/dl for men 
                                       >50 mg/dl for women 
          Total cholesterol  <200mg/dl 
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Statistical Tools 
• The data collected regarding all the selected cases was recorded in a  
Master Chart. Data analysis was done with the help of computer using standard 
SPSS software package ( Statistics Products Services Solutions). 
• Using this software range, frequencies, percentages, means, standard  
deviations, ‘T’ test, chi square and 'p' values were calculated.  
• Kruskul Wallis chi-square test was used to test the significance of  
difference between quantitative variables and Yate’s test for qualitative 
variables.  
• 'p' value < 0.05 is taken to denote significant relationship. 
• ‘p’ value <0.01 is taken to denote highly significant relationship. 
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OBSERVATIONS AND ANALYSIS 
STUDY POPULATION CHARACTERISTICS 
               This study included a total of 100 subjects out of which 50 were cases 
(acute ischaemic stroke) and 50 were controls. 
TABLE 1: 
  
Frequency 
 
Percent 
 
Valid 
Percent 
 
Cumulative 
Percent 
Case 50 50 50 50 
Control 50 50 50 50 
Total 100 100 100 100 
 
FIGURE 1: 
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TABLE 2: GENDER WISE DISTRIBUTION OF PATIENTS 
  
Group 
Total Control Cases 
 
 
 
 
 
 
Sex 
 
 
Male 
Count 44 45 89 
% within 
Sex 49.4% 50.6% 100.0% 
% within 
Group 88.0% 90.0% 89.0% 
 
 
Female 
Count 6 5 11 
% within 
Sex 54.5% 45.5% 100.0% 
% within 
Group 12.0% 10.0% 11.0% 
 
 
 
Total 
Count 50 50 100 
% within 
Sex 50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
 
p value – 0.749  ( not significant) 
 
FIGURE 2: GENDER WISE DISTRIBUTION OF PATIENTS 
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                     The 50 cases studied included 45 (90%) males and 5 (10%) 
females. The 50 controls studied included 44 (88%) males and 6 (12%) females.  
There was not statistically significant difference. 
Inference:  
The sex composition of the cases and controls did not differ significantly. 
 
 
TABLE 3: AGE WISE DISTRIBUTION OF PATIENTS 
   
Group 
Total Control Cases 
Age in years <= 40 Count 10 8 18 
% within Age 
in years 55.6% 44.4% 100.0% 
% within 
Group 20.0% 16.0% 18.0% 
41-60 Count 32 29 61 
% within Age 
in years 52.5% 47.5% 100.0% 
% within 
Group 64.0% 58.0% 61.0% 
> 60 Count 8 13 21 
% within Age 
in years 38.1% 61.9% 100.0% 
% within 
Group 16.0% 26.0% 21.0% 
Total Count 50 50 100 
% within Age 
in years 50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
 
p value – 0.458 (not significant) 
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FIGURE 3 : AGE WISE DISTRIBUTION OF PATIENTS 
               
 
               The study population was stratified into 3 groups according to their 
age. The mean age in the case and control groups were 51.98 ± 13.114 and 
51.80 ± 10.633 years respectively. 
Inference:  
No significant difference in the age distribution between the cases and controls 
in all the age groups. 
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TABLE 4:  CASES AND CONTROLS WITH RESPECT TO BMI 
 
BODY MASS INDEX(kg/m2) 
 
Total Normal Overweight Obese 
 
GROUP 
 
Case Count 
% within group 
19 
38% 
17 
34% 
14 
28% 
50 
100% 
Control Count 
% within group 
30 
60% 
17 
34% 
3 
6% 
50 
100% 
Total Count 
% within group 
50 
50% 
32 
32% 
18 
18% 
100 
100% 
 
P value – 0.001 (significant) 
FIGURE 4 : CASES AND CONTROLS WITH RESPECT TO BMI 
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CONTROLS 
 
 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
BMI Control 50 24.5016 2.83610 .40109 
Cases 50 26.8170 3.71224 .52499 
 
Inference: 
The BMI of the study group is significantly higher than that of the control 
group. 
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TABLE 5 : CASES AND CONTROLS WITH RESPECT TO SMOKING 
   
Group 
Total Control Cases 
Smoking Yes Count 36 38 74 
% within 
Smoking 48.6% 51.4% 100.0% 
% within 
Group 72.0% 76.0% 74.0% 
No Count 14 12 26 
% within 
Smoking 53.8% 46.2% 100.0% 
% within 
Group 28.0% 24.0% 26.0% 
Total Count 50 50 100 
% within 
Smoking 50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
 
p value – 0.648 ( not significant ) 
FIGURE 5 : CASES AND CONTROLS WITH RESPECT TO SMOKING 
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        There is no significant difference between the cases and controls with 
reference to smoking. 
Inference:  
We could safely exclude smoking as a confounding factor for cerebrovascular 
risk.  
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TABLE 6 : CASES AND CONTROLS WITH RESPECT TO  
LDL CHOLESTROL 
LDL Group 
 
No. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error 
Mean 
 
 
Cases 
50 133.26 32.855 4.646 
 
Control 
50 118.20 29.596 4.185 
p value – 0.18 ( not significant ) 
 
FIGURE 6 : CASES AND CONTROLS WITH RESPECT TO LDL 
CHOLESTROL 
 
 
148
150
152
154
156
158
160
CASES CONTROLS
LDL CHOLESTROL
LDL CHOLESTROL
77 
 
The mean LDL cholestrol among cases and controls is 133.26 and 118.20 mg/dl 
and a standard deviation of 32.855 and 29.596 respectively, p value – 0.18. 
Inference: 
The difference between the two groups with respect to LDL cholestrol is not 
statistically significant. 
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TABLE 7 : CASES AND CONTROLS WITH RESPECT TO  
HDL CHOLESTROL 
HDL Group 
 
No. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error 
Mean 
 
 
Cases 
50 44.24 5.850 .827 
 
Control 
50 43.86 6.704 .948 
p value – 0.763 (not significant) 
 
FIGURE 7 : CASES AND CONTROLS WITH RESPECT TO  
HDL CHOLESTROL 
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The mean HDL cholestrol among cases and controls is 44.24 and 43.86 mg/dl 
and a standard deviation of 5.85 and 6.704 respectively, p value – 0.763 
Inference:  
The difference between the two groups with respect to HDL cholestrol is not 
statistically significant. 
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TABLE 8 : CASES AND CONTROLS WITH RESPECT TO  
TOTAL CHOLESTROL 
TOTAL 
CHOLESTROL Group 
 
No. 
 
Mean 
 
Std. 
Deviation 
 
Std. Error 
Mean 
 
 
Cases 
50 208.98 31.924 4.515 
 
Control 
50 192.20 27.049 3.825 
p value – 0.006 (significant) 
 
FIGURE 8 : CASES AND CONTROLS WITH RESPECT TO  
TOTAL CHOLESTROL 
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The mean Total Cholestrol among cases and controls is 208.98 and 192.20 
mg/dl and a standard deviation of 31.924 and 27.049 respectively,  
p value – 0.006. 
Inference:  
The difference between cases and controls with respect to total cholestrol is 
statistically significant. 
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TABLE 9 : CASES AND CONTROLS WITH RESPECT TO  
TRIGLYCERIDES 
TRIGLYCERIDE 
Group 
 
No. 
 
Mean 
 
Std. 
Deviation 
 
Std. 
Error 
Mean 
 
 
Cases 
50 159.10 40.861 5.779 
 
Control 
50 152.58 58.968 8.339 
p value – 0.522 (not significant) 
 
FIGURE 9 : CASES AND CONTROLS WITH RESPECT TO  
TRIGLYCERIDES 
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The mean Triglyceride level among cases and controls is 159.10 and 152.58 
mg/dl and a standard deviation of 40.861 and 58.968 respectively, and p value is 
0.522. 
Inference: 
The difference between cases and controls with respect to Triglyceride level is 
not statistically significant. 
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TABLE 10 : VITAMIN D STATUS IN THE STUDY POPULATION 
   
Group 
Total Control Cases 
VIT D Level Normal Count 12 0 12 
% within VIT 
D Level 100.0% .0% 100.0% 
% within 
Group 24.0% .0% 12.0% 
Insufficient Count 33 34 67 
% within VIT 
D Level 49.3% 50.7% 100.0% 
% within 
Group 66.0% 68.0% 67.0% 
Deficient Count 5 16 21 
% within VIT 
D Level 23.8% 76.2% 100.0% 
% within 
Group 10.0% 32.0% 21.0% 
Total Count 50 50 100 
% within VIT 
D Level 50.0% 50.0% 100.0% 
% within 
Group 100.0% 100.0% 100.0% 
p value – 0.001 ( highly significant) 
FIGURE 10: VITAMIN D STATUS IN THE STUDY POPULATION 
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Cases: 
Vitamin D normal – none 
Vitamin D insufficiency – 68% 
Vitamin D deficiency – 32% 
Controls: 
Vitamin D normal – 24% 
Vitamin D insufficiency – 66% 
Vitamin D deficiency – 10% 
The mean serum 25 hydroxy Vitamin D in the cases and controls is  
13.48 ± 5.34ng/ml and 23.03 ± 11.28ng/ml respectively with a p value of 0.001. 
Inference: 
The difference between cases and controls with respect to Vitamin D is 
statistically highly significant. 
This means that significant hypovitaminosis D is seen among the cases. 
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TABLE 11: GENDERWISE DISTRIBUTION OF VITAMIN D 
   
VIT D Level 
Total Normal Below Normal 
Sex Male Count 11 78 89 
% within Sex 12.4% 87.6% 100.0% 
% within VIT 
D Level 91.7% 88.6% 89.0% 
Female Count 1 10 11 
% within Sex 9.1% 90.9% 100.0% 
% within VIT 
D Level 8.3% 11.4% 11.0% 
Total Count 12 88 100 
% within Sex 12.0% 88.0% 100.0% 
% within VIT 
D Level 100.0% 100.0% 100.0% 
p value – 0.753 (not significant) 
FIGURE 11: GENDERWISE DISTRIBUTION OF VITAMIN D 
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Out of the 89 males included in the study, 11 had normal Vitamin D levels and 
78 had below normal levels of Vitamin D. 
Out of the 11 females included in the study, 1 had normal Vitamin D level and 
10 had below normal levels of Vitamin D. 
 
Inference: 
No significant difference in Vitamin D levels between males and females. 
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TABLE 12: VITAMIN D STATUS IN EACH AGE GROUP 
   
VIT D Level 
Total Normal Below Normal 
Age in years ≤40 Count 2 16 18 
% within Age 
in years 11.1% 88.9% 100.0% 
% within VIT 
D Level 16.7% 18.2% 18.0% 
41-60 Count 8 53 61 
% within Age 
in years 13.1% 86.9% 100.0% 
% within VIT 
D Level 66.7% 60.2% 61.0% 
> 60 Count 2 19 21 
% within Age 
in years 9.5% 90.5% 100.0% 
% within VIT 
D Level 16.7% 21.6% 21.0% 
Total Count 12 88 100 
% within Age 
in years 12.0% 88.0% 100.0% 
% within VIT 
D Level 100.0% 100.0% 100.0% 
p value – 0.046 (significant) 
FIGURE 12: VITAMIN D STATUS IN EACH AGE GROUP 
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• In the age group 41-60 yrs, 88.9% subjects had below normal levels of  
Vitamin D. 
• In the age group ≤ 40 yrs, 86.9% subjects had below normal levels of  
Vitamin D. 
• In the age group >60 yrs, 90.5% subjects had below normal levels of  
Vitamin D. 
• p value of 0.046 
Inference: 
Significant degree of Vitamin D deficiency is seen among all age groups with 
the level of deficiency being more significant in the cases with age less than 
40yrs. 
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TABLE 13: CORRELATION BETWEEN VITAMIN D STATUS AND 
BODY MASS INDEX (BMI) 
 
VIT D 
Level No. Mean Std. Deviation 
Std. Error 
Mean 
BMI Normal 12 24.2400 2.21329 .63892 
Below 
Normal 88 25.8528 3.59127 .38283 
P value – 0.133 (not significant) 
FIGURE 13: CORRELATION BETWEEN VITAMIN D STATUS AND 
BODY MASS INDEX (BMI) 
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The mean BMI value among subjects in normal Vitamin D and below normal 
Vitamin D levels is 24.24 ±2.21 and 25.85 ± 3.59, respectively, with p value  
of  0.133. 
Inference: 
• There is no significant difference in BMI between subjects with normal 
Vitamin D levels and subjects with below normal Vitamin D levels. 
 No significant correlation between Vitamin D levels and BMI. 
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TABLE 14: CORRELATION BETWEEN VITAMIN D STATUS AND 
LDL CHOLESTROL 
 
VIT D 
Level N Mean Std. Deviation 
Std. Error 
Mean 
LDL Normal 12 113.25 27.110 7.826 
Below 
Normal 88 127.43 32.391 3.453 
p value – 0.151 (not significant) 
 
FIGURE 14: CORRELATION BETWEEN VITAMIN D STATUS AND 
LDL CHOLESTROL 
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The mean BMI value among subjects in normal Vitamin D and below normal 
Vitamin D levels is 113.25 ±27.11 and 127.43 ± 32.39, respectively, with p 
value of  0.151. 
Inference: 
• There is no significant difference in LDL Cholestrol levels between 
subjects with normal Vitamin D levels and subjects with below normal 
Vitamin D levels. 
 No significant correlation between Vitamin D levels and LDL Cholestrol. 
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TABLE 15: CORRELATION BETWEEN VITAMIN D STATUS AND 
HDL CHOLESTROL 
 
VIT D 
Level N Mean Std. Deviation 
Std. Error 
Mean 
HDL Normal 12 45.08 7.255 2.094 
Below 
Normal 88 43.91 6.149 .655 
p value – 0.545 (not significant) 
 
FIGURE 15: CORRELATION BETWEEN VITAMIN D STATUS AND 
HDL CHOLESTROL 
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The mean BMI value among subjects in normal Vitamin D and below normal 
Vitamin D levels is 45.08 ± 7.25 and 43.91 ± 6.14, respectively, with p value  
of  0.545. 
Inference: 
• There is no significant difference in HDL Cholestrol levels between 
subjects with normal Vitamin D levels and subjects with below normal 
Vitamin D levels. 
 No significant correlation between Vitamin D levels and HDL Cholestrol. 
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TABLE 16: CORRELATION BETWEEN VITAMIN D STATUS AND 
TOTAL CHOLESTROL 
 
VIT D 
Level N Mean Std. Deviation 
Std. Error 
Mean 
TC Normal 12 192.83 24.357 7.031 
Below 
Normal 88 201.65 31.346 3.342 
p value – 0.352 (not significant) 
 
FIGURE 16: CORRELATION BETWEEN VITAMIN D STATUS AND 
TOTAL CHOLESTROL 
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The mean BMI value among subjects in normal Vitamin D and below normal 
Vitamin D levels is 192.83 ±24.35 and 201.65 ± 31.34, respectively, with p 
value of  0.352. 
Inference: 
• There is no significant difference in Total Cholestrol levels between 
subjects with normal Vitamin D levels and subjects with below normal 
Vitamin D levels. 
 No significant correlation between Vitamin D levels and Total Cholestrol. 
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TABLE 17: CORRELATION BETWEEN VITAMIN D STATUS AND 
TRIGLYCERIDE LEVEL 
 
VIT D 
Level N Mean Std. Deviation 
Std. Error 
Mean 
Trigly Normal 12 174.25 72.473 20.921 
Below 
Normal 88 183.33 46.838 4.993 
p value – 0.180 (not significant) 
 
FIGURE 17: CORRELATION BETWEEN VITAMIN D STATUS AND 
TRIGLYCERIDE LEVEL 
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The mean BMI value among subjects in normal Vitamin D and below normal 
Vitamin D levels is 174.25 ± 72.47 and 183.33 ± 46.83, respectively, with p 
value of  0.180. 
Inference: 
• There is no significant difference in Triglyceride levels between subjects 
with normal Vitamin D levels and subjects with below normal Vitamin D 
levels. 
 No significant correlation between Vitamin D and Triglyceride levels. 
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TABLE 18: CORRELATION BETWEEN VITAMIN D STATUS AND 
AREA OF INFARCT 
   
VIT D Level 
Total Normal Below Normal 
Area of 
Infarct 
MCA Count 0 78 78 
% within Area 
of Infarct  100.0% 100.0% 
% within VIT 
D Level  78.0% 78.0% 
ACA Count 0 8 8 
% within Area 
of Infarct  100.0% 100.0% 
% within VIT 
D Level  8.0% 8.0% 
PCA Count 0 14 14 
% within Area 
of Infarct  100.0% 100.0% 
% within VIT 
D Level  14.0% 14.0% 
Total Count 0 100 100 
% within Area 
of Infarct  100.0% 100.0% 
% within VIT 
D Level  100.0% 100.0% 
p value – 0.049 (significant) 
FIGURE 18: CORRELATION BETWEEN VITAMIN D STATUS AND 
TERRITORY (AREA) OF INFARCT 
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Among all the cases, 78% had MCA infarct, 8% had ACA infarct and 14% had 
PCA infarct. 
p value – 0.049 (significant) 
Inference: 
There is significant correlation between Vitamin D levels and territory (area) of 
infarct. 
Cases with below normal Vitamin D levels have infarcts involving the MCA 
territory mainly. 
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DISCUSSION 
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DISCUSSION 
 In our study of 100 patients, 50 cases with acute ischaemic stroke and 50 
age and sex matched controls were included. We had selected our cases in such 
a way that they had no history of systemic hypertension, diabetes mellitus, 
chronic kidney disease, coronary artery disease or prior stroke. This was done to 
study whether low Vitamin D levels could be an independent risk factor for the 
occurrence of cerebro vascular accident in patients. 
VITAMIN D AND STROKE 
 We found a statistically significant correlation between below normal 
Vitamin D levels and Acute Ischaemic Stroke. All the patients who were 
admitted with acute ischaemic stroke had below normal Vitamin D levels. 
Vitamin D deficiency (<10ng/ml) was seen in 32% of the cases and 26% of the 
controls. Among the controls, 10% had Vitamin D deficiency, 66% had Vitamin 
D insufficiency and only 24% had normal Vitamin D levels. The mean Vitamin 
D levels among cases and controls was 13.48 and 23.03ng/ml respectively with 
a statistically significant difference. 
 Study done by Tu WJ et al51 showed a Vitamin D level of 10-18ng/ml 
among stroke cases and 17-22ng/ml among controls. Kenneth et al49 found 
77% prevalence of Vitamin D deficiency among stroke patients whereas the 
prevalence is 100% in our study. 
104 
 
Studies done by Pilz et al50, de Silva et al55 and LURIC study53 showed 
a Vitamin D deficiency in 58%, 95% and 92% respectively among stroke 
patients.  
 On assessing the overall study population of 100 subjects, we found only 
12% of the subjects had normal Vitamin D levels. The remaining 88% had 
below normal Vitamin D levels with 21% having Vitamin D deficiency and 
67% Vitamin D insufficiency. This high rate of Vitamin D deficiency in our 
study group reflects the high prevalence of Vitamin D deficiency in Indian 
population as already demonstrated by Harinarayan et al39 showing prevalence 
of Vitamin D deficiency to be around 50-90% among Indian population.62 
 The control group showed a mean Vitamin D level of 23.03ng/ml. This is 
similar to the mean value of 24ng/ml among apparently healthy subjects shown 
by the NHANES 2005-2006 survey54.  
 In our study, the association between ischaemic stroke and parameters 
like Gender, Age, Body Mass Index, Smoking, LDL cholestrol, HDL cholestrol, 
Total cholestrol, Triglycerides and Area of infarct was also analysed. Apart 
from Body Mass Index, statistical significance was not found with any other 
parameter. Hence we could safely exclude most of these confounding factors, 
which are themselves independent risk factors of stroke.  
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The association between Vitamin D and parameters like Gender, Age, 
Body Mass Index, Smoking, LDL cholestrol, HDL cholestrol, Total cholestrol, 
Triglycerides and Area of infarct was also analysed in our study. 
VITAMIN D AND GENDER VARIATION  
We did not find any significant association between Vitamin D levels and 
gender distribution. Normal Vitamin D levels were found in 12% of males and 
9% of females. 88% of males and 91% of females had below normal Vitamin D 
levels. This is contrary to the study done by Johnson et al47 which showed 
significant Vitamin D deficiency among men than women. 
VITAMIN D AND AGE DISTRIBUTION  
The study population was divided into 3 age groups ( <40yrs, 41-60yrs, 
>60yrs). Below normal Vitamin D levels were found in the three age groups 
were 89%, 87% and 90% respectively. There was significant hypovitaminosis D 
in the young stroke patients (<40yrs of age). This showed Vitamin D deficiency 
as an independent risk factor for young stroke in the absence of other 
conventional risk factors. On the contrary, Harinarayan et al39 didnot find any 
significant difference among various age groups. 
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VITAMIN D AND SMOKING 
There was no significant association between Vitamin D and smoking in 
our study. But a study done by Eugenia Cutillas et al48 had shown significant 
Vitamin D deficiency in smokers. 
VITAMIN D AND OBESITY 
 Body Mass Index was found to higher in subjects with below normal 
Vitamin D levels. Body mass index >25kg/m2 was seen in approximately 70% 
of the subjects with Vitamin D deficiency. But high BMI values were not 
statistically significant. This is not in concurrence with many studies that link 
high BMI(obesity) to Vitamin D deficiency. Obesity can itself lead to 
atherosclerosis and cause stroke. Thus, our study showed association between 
Vitamin D deficiency and stroke, without significant effect of Vitamin D on 
Body Mass Index. Studies done by Calin et al and Aasheim et al48 had shown 
people with Vitamin D deficiency having high BMI values. 
VITAMIN D AND DYSLIPIDEMIA 
 We did not find any association between Vitamin D and dyslipidemia 
(LDL cholestrol, HDL cholestrol, Total cholestrol, Triglycerides). But  studies 
done by Chaudhuri et al71 and Zittermann et al72 shown dyslipidemia in 
patients with Vitamin D deficiency.  
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VITAMIN D AND TERRITORY OF INFARCT 
 Association between Vitamin D deficiency and territory of infarct was 
significant (p-0.049) with most of the cases with Vitamin D deficiency having 
MCA territory infarct. We could not get any previous study relating the territory 
of infarct to Vitamin D deficiency. Probably our study is one of the first few 
studies to identify the correlation between Vitamin D deficiency and area of 
infarct.  
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CONCLUSION 
• A wide variety of diseases are associated with Vitamin D deficiency. 
This poses a great burden on the community. Hence, the discovery of the 
causal association of Vitamin D deficiency in stroke is indeed an 
important breakthrough. 
• In our study, ischaemic stroke patients had significantly low levels of 
Vitamin D. 
• There is growing body of evidence suggesting low Vitamin D levels may 
be a potentially modifiable cerebrovascular risk factor. Our results 
provide additional evidence to this. 
• These results may have broad public health implications due to the high 
prevalence of Vitamin D deficiency in our country. 
• Vitamin D deficiency is an easily measurable and correctable risk 
factor. The treatment is cost effective and safe. Therefore, general 
awareness needs to be created about this risk factor and guidelines need 
to be implemented regarding its diagnosis and treatment. 
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• Adequate sun exposure and food fortification are simple preventive 
measures which can bring about a significant reduction in 
cerebrovascular events and other diseases associated with Vitamin D 
deficiency. 
• Large scale randomized control trials are needed to further analyse 
Vitamin D deficiency as a risk factor for stroke and the effects of Vitamin 
D supplementation on the prevention of stroke. 
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LIMITATIONS OF THE STUDY 
• The main limitation in our study is the small number of subjects 
included in the study. 
• Female patients included in the study were very few in number. Further 
studies need to be done including larger number of women. 
• Parathormone levels were not measured. Hence its role as a confounding 
factor could not be analysed. 
• The cause for the below normal Vitamin D in the subjects was not 
evaluated. 
• We could not assess the prognosis of the patients after Vitamin D 
supplementation as they were not followed up. 
• The etiology for ischaemic stroke in the young patients was not studied 
and so we could not rule our other possible confounding factors. 
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IMPLICATIONS FOR THE FUTURE 
• Measurement of serum 25 hydroxy Vitamin D levels should be routinely 
done in all patients with Diabetes mellitus, systemic hypertension, 
dyslipidemia and other stroke risk factors because early detection and 
correction of deficiency states has proven beneficial effects in preventing 
the occurence of stroke. 
• Estimation of Vitamin D levels in the general population could help 
identify low normal levels and correct the deficit, so that, conditions like 
diabetes mellitus, systemic hypertension, coronary heart disease and 
ischaemic stroke can be prevented. Further large scale studies are needed 
to firmly implement the need to measure Viatmin D levels in the general 
population. 
• India is a developing country with high incidence of stroke in urban and 
rural population where poverty and illeteracy dominate. Therefore public 
health awareness programs and food fortification programs need to be 
implemented to overcome this deficit. 
• Vitamin D - Food fortification programs is the need of the hour in our 
country.  Many developed countries have already initiated fortification of 
foods such as milk and dairy products with Vitamin D. This is a very 
efficient method to reduce the incidence of Vitamin D deficiency mainly 
in people on a pure vegetarian diet.  
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ABBREVIATIONS 
rt-PA   - recombinant tissue plasminogen activator 
WHO  - World Health Organisation 
ICMR - Indian Council of Medical Research 
RDA  - Recommended Daily Allowance 
LDL  - Low Density Lipoprotein 
HDL  - High Density Lipoprotein 
TGL  - Triglycerides 
TC  - Total Cholestrol 
BMD  - Bone Mineral Density 
GCS  - Glascow Coma Scale 
25(OH)D - 25 hydroxy Vitamin D 
TGF  - Transforming Growth Factor 
UVB  - Ultraviolet B 
PTH  - Parathormone 
NCD  - Non Communicable Disease 
TNF  - Tumor Necrosis Factor 
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DATA COLLECTION FORM (PROFORMA) 
NAME:       
AGE:   
SEX: 
OCCUPATION: 
ADDRESS:        
IP.No.: 
DATE OF ADMISSION: 
DATE OF EVENT OF STROKE: 
H/O Smoking: 
Height (m): 
Weight (kg): 
BMI (kg/m2): 
LDL cholestrol: 
HDL cholestrol: 
Triglycerides: 
Total Cholestrol: 
Serum Vitamin D: 
 
CT BRAIN: 
(area of infarct) 
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PATIENT CONSENT FORM 
STUDY DETAIL: 
STUDY CENTRE: 
PATIENT’S NAME: 
PATIENT’S AGE: 
IDENTIFICATION NUMBER: 
I confirm that I have understood the purpose and procedure of the above 
study. I have the opportunity to ask questions and all my questions and doubts 
have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of the 
current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study I agree to this access. However I understand 
that my identity would not be revealed in any information released to third 
parties or published, unless as required under the law. I agree not to restrict 
the use of any data or results that arise from this study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological tests. 
Signature/thumb impression: 
Patient’s name and address:                                         Place:                              Date: 
Signature of the investigator: 
Name of the investigator:                                              Place:                              Date: 
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1 Jeyakumar 26 M 31.24 Y 111 46 169 190 10.09 MCA
2 Selvaraj 74 M 26.67 N 129 42 109 192 27.39 MCA
3 Suresh 27 M 21.34 Y 129 38 165 200 8.26 PCA
4 Arumugam 57 M 24.91 Y 101 45 135 173 19.32 MCA
5 Sahul Hameed 46 M 24.77 Y 91 52 110 165 11.88 MCA
6 Deenadayalan 60 M 30.52 Y 99 47 135 173 7.28 PCA
7 Dorairaj 58 M 24.69 Y 92 40 96 151 18.2 MCA
8 Ravi 53 M 28.85 Y 132 37 115 192 11.08 MCA
9 Palani 43 M 21.26 N 91 39 160 162 28.32 MCA
10 Chelladurai 33 M 23'05 Y 181 34 154 245 8.94 MCA
11 Sambantham 59 M 29.43 Y 158 38 120 220 14.86 MCA
12 Sriramulu 70 M 29.52 Y 223 30 110 275 21.71 MCA
13 Mary 60 F 29.3 N 209 47 174 290 14.1 MCA
14 Arivudainambi 43 M 30.78 Y 219 41 127 285 10.35 PCA
15 Ismail 42 M 31.56 Y 150 43 87 210 7.91 MCA
16 Maria 65 F 32.89 N 154 49 210 245 12.21 MCA
17 Palanivel 60 M 27.67 Y 132 44 198 215 9.68 MCA
18 Swaminathan 62 M 29.9 N 128 51 201 219 24.39 MCA
19 Subramani 80 M 20.05 N 116 49 150 195 14.08 MCA
20 Babu 42 M 34.5 Y 106 47 135 180 15.96 ACA
21 Rajkumar 56 M 31.87 Y 94 51 135 172 7.93 MCA
22 Jeganathan 43 M 30.08 Y 186 37 208 264 15.77 PCA
23 Chandran 65 M 23.34 N 112 48 163 192 16.2 MCA
24 Iqbal Basha 52 M 27.56 Y 92 46 140 166 18.12 MCA
25 Kathirvel 50 M 27.81 Y 125 41 158 197 10.92 MCA
26 Sekar 67 M 24.52 Y 125 49 183 210 7.6 MCA
27 Lakshmi 70 F 29.9 N 103 56 148 188 9.23 MCA
28 Paramasivam 53 M 28.03 Y 111 47 145 187 13.87 MCA
29 Palani 62 M 21.89 Y 114 39 200 193 12.11 MCA
30 Muthukumar 49 M 32.15 Y 163 49 136 239 6.57 ACA
31 Velu 30 M 27.82 Y 171 38 128 234 10.97 PCA
32 Sekar 45 M 27.8 Y 171 41 136 239 7.19 MCA
33 Dhanapal 67 M 25.92 Y 134 43 109 198 13.15 MCA
34 Koti 56 M 30.05 Y 94 50 139 171 9.38 MCA
35 Saif 54 M 22.87 Y 141 36 246 226 20.6 MCA
36 Balaji 36 M 20.14 Y 120 39 236 206 10.3 MCA
37 Perumal 58 M 22.43 Y 131 43 237 221 15.76 PCA
38 Mala 62 F 24.78 N 108 53 158 192 15.1 MCA
39 Sahira Banu 42 F 25.5 Y 102 57 140 187 9.79 MCA
40 Kali 29 M 23.73 Y 123 42 225 210 7.62 MCA
41 Babu 42 M 24.19 Y 117 47 106 185 11.23 MCA
42 Md.Talip 45 M 20.95 Y 142 44 124 210 16.17 MCA
43 Basha 35 M 24.91 N 140 51 145 220 20.14 PCA
44 Vincent 63 M 23.5 Y 148 39 228 232 18.94 MCA
45 Murugan 74 M 28.73 Y 168 37 187 242 10.03 PCA
46 Srikanth 59 M 32.3 N 153 45 204 238 9.56 MCA
47 Dhanasekar 46 M 23.17 Y 145 41 224 230 21.09 MCA
48 Munusamy 37 M 25.67 N 151 49 198 239 15.43 ACA
49 Hariharan 41 M 29.78 Y 118 52 149 199 8.47 MCA
50 Pratap 51 M 26.56 Y 110 43 160 185 9.22 MCA
CONTROLS
S.No. NAME AGE SEX BMI SMOKING LDL HDL TRIGLY TC VIT D LEVEL
1 Nataraj 67 M 25.09 N 93 44 105 158 16.47
2 Ravikumar 40 M 23.07 Y 93 48 111 163 20.02
3 araman 40 M 23.45 Y 123 41 93 182 30.8
4 Ganesh 35 M 24.15 Y 106 46 103 172 23.29
5 Sivaraman 46 M 26.89 Y 143 53 144 224 13.41
6 Govindsamy 52 M 22.51 Y 130 38 110 190 49.23
7 Kandamani 60 F 22.92 N 150 49 101 219 15.17
8 Mani 65 M 23.34 N 107 50 138 184 25.26
9 Pachiannan 55 M 19.87 Y 99 47 96 165 27.38
10 Moorthy 42 M 21.34 Y 108 38 119 169 9.18
11 Chandran 35 M 24.22 N 123 31 112 176 20.7
12 Sardar 55 M 20,08 Y 106 45 105 172 19.77
13 Abdul 60 M 30.87 Y 200 37 99 256 15.2
14 Bhaskar 52 M 25.56 N 138 41 117 202 33.06
15 Ellappan 74 M 27.8 N 103 53 98 175 35.43
16 kumar 52 M 29.49 Y 101 49 92 168 10.03
17 Pandian 55 M 30.21 Y 112 43 93 173 13.23
18 Sivakumar 52 M 27.68 Y 129 47 120 200 9.83
19 Mani 52 M 26.22 N 109 46 122 179 13.19
20 Kanniappan 48 M 21.34 Y 150 39 103 209 18.66
21 Muthusamy 75 M 23.8 N 102 41 108 164 23.37
22 Mariappan 60 M 24.49 Y 91 45 223 180 11.5
23 Gangaiyan 70 M 21.37 N 138 38 235 223 19.66
24 Vasu 40 M 26.67 Y 125 40 135 192 20.17
25 Manohar 48 M 27.93 Y 179 32 251 261 43.62
26 Srinivas 46 M 22.92 Y 135 35 142 198 10.15
27 Meena 51 F 24.56 N 90 54 213 186 16.06
28 Subramani 58 M 19.87 Y 115 37 139 179 10.79
29 Meera 52 F 23.47 N 91 51 246 191 8.22
30 James 52 M 21.9 Y 91 42 222 177 51.7
31 Vanaraj 60 M 23.5 Y 111 35 124 170 8.56
32 Kamaraj 34 M 22.89 Y 133 41 154 204 29.33
33 Pichai 70 M 21.16 Y 83 50 240 181 36.78
34 Manickam 55 M 20.86 Y 145 39 170 218 28.14
35 Surendar 42 F 25.54 Y 71 56 230 173 28.5
36 Sarada 62 M 22.68 Y 82 49 105 152 18.78
37 Ponraj 48 M 22.71 Y 94 51 115 168 34.89
38 Raman 45 M 23.34 Y 92 47 96 158 26.73
39 Latha 50 F 26.12 Y 96 58 282 210 41.7
40 Ganesh 55 M 23.53 Y 122 41 123 187 35.6
41 Dilli Babu 60 M 28.12 Y 123 43 274 220 12.8
42 Chinnasamy 62 M 30.09 Y 197 35 150 262 20.93
43 Kolandaivel 51 M 25.2 Y 160 33 110 215 23.45
44 Kalyan 48 M 24.76 N 109 48 178 192 39.88
45 Vijaykumar 34 M 23.45 Y 91 46 262 189 42.56
46 Noor 40 F 24.9 N 140 57 159 228 21.67
47 Sampath 56 M 26.57 Y 166 39 128 230 8.93
48 Shankar 30 M 28.85 Y 143 36 235 226 16.72
49 Jayavendan 59 M 20.43 Y 103 41 140 172 19.87
50 Rajesh 40 M 27.3 N 69 48 259 168 21.31

